AU2008293038B2 - Inhibitors of protein tyrosine kinase activity - Google Patents

Inhibitors of protein tyrosine kinase activity Download PDF

Info

Publication number
AU2008293038B2
AU2008293038B2 AU2008293038A AU2008293038A AU2008293038B2 AU 2008293038 B2 AU2008293038 B2 AU 2008293038B2 AU 2008293038 A AU2008293038 A AU 2008293038A AU 2008293038 A AU2008293038 A AU 2008293038A AU 2008293038 B2 AU2008293038 B2 AU 2008293038B2
Authority
AU
Australia
Prior art keywords
alkyl
optionally substituted
alternatively
group
meo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008293038A
Other languages
English (en)
Other versions
AU2008293038A1 (en
Inventor
Stephen William Claridge
Robert Deziel
Frederic Gaudette
Ljubomir Isakovic
Michael Mannion
Franck Raeppel
Stephane Raeppel
Oscar Mario Saavedra
Tetsuyuki Uno
Arkadii Vaisburg
Lijie Zhan
Nancy Z. Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of AU2008293038A1 publication Critical patent/AU2008293038A1/en
Assigned to METHYLGENE INC. reassignment METHYLGENE INC. Request for Assignment Assignors: METHYLGENE INC.
Application granted granted Critical
Publication of AU2008293038B2 publication Critical patent/AU2008293038B2/en
Assigned to Mirati Therapeutics, Inc. reassignment Mirati Therapeutics, Inc. Request for Assignment Assignors: METHYLGENE INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008293038A 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity Active AU2008293038B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96867307P 2007-08-29 2007-08-29
US60/968,673 2007-08-29
PCT/CA2008/001538 WO2009026717A1 (en) 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity

Publications (2)

Publication Number Publication Date
AU2008293038A1 AU2008293038A1 (en) 2009-03-05
AU2008293038B2 true AU2008293038B2 (en) 2013-08-29

Family

ID=40386626

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008293038A Active AU2008293038B2 (en) 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity

Country Status (19)

Country Link
US (3) US8404846B2 (enExample)
EP (1) EP2183254B1 (enExample)
JP (1) JP5656634B2 (enExample)
KR (1) KR101556269B1 (enExample)
CN (3) CN101932586A (enExample)
AR (1) AR068066A1 (enExample)
AU (1) AU2008293038B2 (enExample)
BR (1) BRPI0816064B8 (enExample)
CA (1) CA2697795C (enExample)
DK (1) DK2183254T3 (enExample)
ES (1) ES2635131T3 (enExample)
IL (1) IL204192A (enExample)
MX (1) MX2010002427A (enExample)
MY (1) MY156536A (enExample)
PL (1) PL2183254T3 (enExample)
RU (1) RU2495044C2 (enExample)
TW (1) TWI571468B (enExample)
WO (1) WO2009026717A1 (enExample)
ZA (1) ZA201001512B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923670A2 (pt) * 2008-03-05 2013-07-30 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos
WO2010045095A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
CA2752421C (en) * 2009-03-21 2013-08-06 Ning Xi Amino ester derivatives, salts thereof and methods of use
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
JP5868855B2 (ja) * 2009-09-03 2016-02-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ チロシンキナーゼ調節剤としての化合物
MY157319A (en) * 2010-04-16 2016-05-31 Methylgene Inc Inhibitors of protein tyrosine kinase activity
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
JP6158705B2 (ja) * 2010-09-27 2017-07-05 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
CA2812744A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2621482A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CA2969540C (en) 2014-12-02 2023-03-21 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
WO2019182274A1 (en) 2018-03-08 2019-09-26 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
CA3100766A1 (en) 2018-05-23 2019-11-28 Beigene, Ltd. Anti-ox40 antibodies and methods of use
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物
US20230172914A1 (en) 2019-09-06 2023-06-08 Wellmarker Bio Co., Ltd. Biomarker-based therapeutic composition
CA3150267A1 (en) * 2019-09-10 2021-03-18 Stephane L. Raeppel Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
US20230022859A1 (en) * 2019-11-21 2023-01-26 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
CN114945576B (zh) * 2020-01-07 2023-10-13 南京明德新药研发有限公司 氘代噻吩并吡啶类化合物
EP4213844A4 (en) 2020-09-17 2024-11-20 Mirati Therapeutics, Inc. POLYTHERAPIES
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof
WO2023155777A1 (en) * 2022-02-15 2023-08-24 Beigene (Suzhou) Co., Ltd. N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2571680A1 (en) * 2004-06-28 2006-01-12 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
CA2611370A1 (en) * 2005-05-20 2006-11-20 Oscar Mario Saavedra Inhibitors of vegf receptor and hgf receptor signaling
US20070197537A1 (en) * 2006-01-30 2007-08-23 Blake James F Heterobicyclic thiophene compounds and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
BRPI0209216B8 (pt) 2001-04-27 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
CA2468989A1 (en) * 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
ES2436888T3 (es) 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
CN1906167A (zh) 2004-02-27 2007-01-31 卫材株式会社 新型吡啶衍生物及嘧啶衍生物(2)
US8940896B2 (en) * 2004-03-15 2015-01-27 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1904504B1 (en) * 2005-05-20 2014-03-19 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
BRPI0616799B8 (pt) 2005-08-24 2021-05-25 Eisai R&D Man Co Ltd derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
JP2010507618A (ja) 2006-10-27 2010-03-11 グラクソ グループ リミテッド ｃ−Ｍｅｔキナーゼ阻害薬としての７−アザインドール誘導体
MY157319A (en) * 2010-04-16 2016-05-31 Methylgene Inc Inhibitors of protein tyrosine kinase activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2571680A1 (en) * 2004-06-28 2006-01-12 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
CA2611370A1 (en) * 2005-05-20 2006-11-20 Oscar Mario Saavedra Inhibitors of vegf receptor and hgf receptor signaling
US20070197537A1 (en) * 2006-01-30 2007-08-23 Blake James F Heterobicyclic thiophene compounds and methods of use

Also Published As

Publication number Publication date
DK2183254T3 (en) 2017-09-11
EP2183254B1 (en) 2017-06-21
EP2183254A1 (en) 2010-05-12
EP2183254A4 (en) 2011-09-28
AR068066A1 (es) 2009-11-04
US20130165477A1 (en) 2013-06-27
TWI571468B (zh) 2017-02-21
CA2697795A1 (en) 2009-03-05
AU2008293038A1 (en) 2009-03-05
JP2010536887A (ja) 2010-12-02
ES2635131T3 (es) 2017-10-02
MX2010002427A (es) 2010-03-30
WO2009026717A1 (en) 2009-03-05
BRPI0816064A2 (pt) 2015-03-31
US20090264440A1 (en) 2009-10-22
US8846927B2 (en) 2014-09-30
CA2697795C (en) 2016-08-16
TW200914458A (en) 2009-04-01
CN105777776A (zh) 2016-07-20
CN101932586A (zh) 2010-12-29
RU2495044C2 (ru) 2013-10-10
JP5656634B2 (ja) 2015-01-21
CN105777776B (zh) 2021-06-08
US20120108628A1 (en) 2012-05-03
MY156536A (en) 2016-02-26
US8389541B2 (en) 2013-03-05
RU2010111729A (ru) 2011-10-10
CN109970759A (zh) 2019-07-05
KR101556269B1 (ko) 2015-09-30
BRPI0816064B1 (pt) 2020-01-28
IL204192A (en) 2016-08-31
KR20100075873A (ko) 2010-07-05
BRPI0816064B8 (pt) 2021-05-25
ZA201001512B (en) 2010-11-24
US8404846B2 (en) 2013-03-26
PL2183254T3 (pl) 2017-10-31

Similar Documents

Publication Publication Date Title
AU2008293038B2 (en) Inhibitors of protein tyrosine kinase activity
AU2010246540B2 (en) Inhibitors of protein tyrosine kinase activity
HK1139407B (en) Inhibitors of protein tyrosine kinase activity
HK1139407A (en) Inhibitors of protein tyrosine kinase activity
HK1155977A (en) Inhibitors of protein tyrosine kinase activity

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: METHYLGENE INC.

Free format text: FORMER APPLICANT(S): METHYLGENE INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MIRATI THERAPEUTICS, INC.

Free format text: FORMER OWNER(S): METHYLGENE INC.